Welcome to Keenova Therapeutics
In an exciting announcement, Mallinckrodt plc has successfully completed the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses. As of now, the company will operate under the new name, Keenova Therapeutics, dedicating its efforts towards developing and delivering innovative therapies for patients with rare or unaddressed health conditions.
Siggi Olafsson, the President and Chief Executive Officer, expressed his pride in unveiling Keenova Therapeutics, reflecting a commitment to patient care and innovation. He noted, "The name 'Keenova' signifies our sharp focus on enhancing patient experiences and exhibiting the creativity required to advance our therapeutic offerings. Our mantra, 'Keen to Solve, Keen to Serve,' embodies our dedication to overcoming patient challenges with integrity and compassion."
Growth Prospects and Future Plans
Keenova Therapeutics has set its sights on a public equity listing on the New York Stock Exchange, anticipated for 2026, pending approval from its Board of Directors. This upcoming listing aims to facilitate further growth and potential public offerings, showcasing the company's readiness to engage with investors and stakeholders.
Olafsson added, "Expressing gratitude to our team for their commitment to making Keenova a reality, we are eager to explore the vast opportunities that lie ahead, not only to support our patients and providers but also to enhance value for our shareholders and partners."
Strategic Positioning in the Market
Keenova's foundation is built on the robust portfolio of branded pharmaceuticals from both Mallinckrodt and Endo, Inc., following their merger completion in mid-2025. With a projected revenue of approximately $1.7 billion for 2024 and a workforce exceeding 1,600 employees, the company is well-positioned for expansion.
The therapeutic offerings from Keenova include notable products such as Acthar Gel, which treats a variety of chronic and acute inflammatory or autoimmune conditions, and XIAFLEX, an innovative injectable treatment targeting specific collagen issues in patients with Dupuytren's contracture and Peyronie's disease.
Expanding the Therapeutics Pipeline
Keenova aims to strengthen its portfolio by pursuing development opportunities across multiple therapeutic areas that exhibit significant unmet needs, including rheumatology, nephrology, and neurology. The strategic approach will be backed by comprehensive commercial capabilities, a quality-first mindset, and solid financial structures, along with an experienced leadership team.
The Role of Advisors
For this transformative transition, Keenova has enlisted Wachtell, Lipton, Rosen & Katz as the lead counsel, with Arthur Cox contributing as Irish counsel, and Hogan Lovells also providing legal expertise.
About Keenova Therapeutics
Keenova Therapeutics operates as a leading developer and manufacturer focused on providing branded therapeutics tailored to help patients facing rare or unaddressed conditions achieve healthier lives. The diverse brand portfolio prioritizes therapeutic areas that require significant attention, addressing needs in immunology, endocrinology, and more. Its headquarters are situated in Dublin, Ireland, and the company boasts manufacturing capabilities across several U.S. states, including Louisiana, New Jersey, and New York.
Furthermore, Keenova emphasizes the importance of its website as a pivotal communication channel, allowing for rapid dissemination of crucial updates, press materials, and investor information, thereby ensuring stakeholders receive timely insights.
Frequently Asked Questions
What is Keenova Therapeutics?
Keenova Therapeutics is the new identity of Mallinckrodt following its spin-off, focusing on branded therapeutics for patients with rare conditions.
When will Keenova pursue a public equity listing?
Keenova plans to pursue a public equity listing on the NYSE in 2026, pending board approval.
What therapeutic areas does Keenova focus on?
Keenova aims to address significant unmet needs in areas like rheumatology, nephrology, and neurology, among others.
Who are the advisors involved in the spin-off?
Wachtell, Lipton, Rosen & Katz serves as the lead counsel, along with Arthur Cox and Hogan Lovells providing legal guidance.
Where is Keenova Therapeutics headquartered?
Keenova Therapeutics has its global headquarters in Dublin, Ireland, with manufacturing facilities across several U.S. states.
